累及部位放疗治疗幽门螺杆菌阴性胃MALT淋巴瘤:178例26年经验
Treatment options for Helicobacter pylori-independent gastric mucosa-associated lymphoid tissue (MALT) lymphoma (GML) include surgery, immunotherapy, chemotherapy, and radiation therapy (RT).…
要点
- 中位随访6.2年,局部失败9.6%,远处病变11.8%。
- 3级毒性仅2例,支持放疗作为标准治疗。
核心结论
- 放疗对幽门螺杆菌阴性胃MALT淋巴瘤高效安全,总生存优良,治疗相关急性或晚期毒性极罕见,支持其作为标准治疗。
研究设计与样本
- 单中心三级癌症转诊中心数据库回顾性研究,纳入1991至2017年接受放疗的幽门螺杆菌阴性胃MALT淋巴瘤患者178例,中位年龄63岁(范围25-89岁)。
主要发现
- 自放疗结束日起5年与10年总生存分别为94%与79%。
- 2例发生3级毒性,2例发生照射野内第二恶性肿瘤。
关键数值与推荐
- 中位放疗剂量3000 cGy,分20次;86%为I期,7%为II期,7%为IV期;放疗后10至12周开始内镜随访。
临床怎么用
- 对幽门螺杆菌阴性胃MALT淋巴瘤可采用累及部位放疗联合常规内镜监测,多数患者单用放疗即可治愈。
局限性
- 为单中心回顾性研究,缺乏前瞻性对照,结论需外推谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment options for Helicobacter pylori-independent gastric mucosa-associated lymphoid tissue (MALT) lymphoma (GML) include surgery, immunotherapy, chemotherapy, and radiation therapy (RT). The purpose of this study was to investigate the efficacy and safety of RT and routine endoscopic surveillance, hypothesizing that most patients are curable with RT alone. We queried a single institution database at a tertiary referral cancer center for patients with H pylori-independent GML treated with RT between 1991 and 2017. Response was assessed by follow-up endoscopies (EGDs) starting 10 to 12 weeks post-RT. Computed tomography scans were also part of the follow-up program, and positron emission tomography was added when clinically appropriate. We identified 178 patients (median age, 63 years; range, 25-89 years); 86% had stage I disease, 7% had stage II disease, and 7% had stage IV disease. Median RT dose was 3000 cGy over 20 fractions. Ninety-five percent of patients exhibited complete pathologic response on posttreatment EGD. Two patients experienced grade 3 toxicity, and 2 patients experienced in-field secondary malignancies. Over a median follow-up of 6.2 years, 9.6% experienced local failures, and 11.8% developed distant sites of disease. Five-year and 10-year overall survival were 94% and 79%, respectively, from last date of RT. RT is a highly effective and safe treatment for GML with excellent overall survival and very rare acute or late treatment-related toxicities. Favorable outcomes from this large retrospective sample of patients provide credible and compelling support for RT as standard of care for H pylori-independent GML.
引用
- Yahalom J, Xu AJ, Noy A, et al. Involved-site radiotherapy for Helicobacter pylori-independent gastric MALT lymphoma: 26 years of experience with 178 patients. Blood Adv. 2021. PMID: 33787863. doi:10.1182/bloodadvances.2020003992
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。